	US 12,433,902 B2
	Liposomal formulations for inhibiting SARS-CoV-2 replication and reducing lung inflammation
Kameswari S. Konduri, Madison, WI (US); Ram Pattisapu, Madison, WI (US); Jogi Pattisapu, Madison, WI (US); and John Zwetchkenbaum, Madison, WI (US)
Assigned to VGSK Technologies, Inc., Madison, WI (US)
Filed by VGSK Technologies, Inc., Madison, WI (US)
Filed on Mar. 13, 2023, as Appl. No. 18/120,770.
Application 18/120,770 is a continuation of application No. PCT/US2022/027838, filed on May 5, 2022.
Claims priority of provisional application 63/184,580, filed on May 5, 2021.
Prior Publication US 2023/0270756 A1, Aug. 31, 2023
Int. Cl. A61K 31/58 (2006.01); A61K 9/127 (2006.01); A61K 31/573 (2006.01); A61K 45/06 (2006.01); A61P 31/14 (2006.01)

CPC A61K 31/58 (2013.01) [A61K 9/127 (2013.01); A61K 31/573 (2013.01); A61K 45/06 (2013.01); A61P 31/14 (2018.01)]

28 Claims

1. A method of targeting delivery of an active agent to a point of viral attachment of a coronavirus to inhibit viral replication, the method comprising:

administering a pharmaceutical composition in a subject in need thereof, wherein the pharmaceutical composition comprises the active agent encapsulated in a liposome carrier,

wherein the liposome carrier comprises phosphatidylglycerol (PG), phosphatidylcholine (PC), and about 1% to about 5% polyethylene glycol distearoylphosphatidylethanolamine (PEG-DSPE), and

wherein the liposome carrier targets alveolar Type II pneumocytes and inhibits viral replication,

thereby targeting delivery of the active agent to the point of viral attachment to inhibit viral replication of the coronavirus.